Lantheus (NASDAQ:LNTH) Price Target Lowered to $109.00 at B. Riley

Lantheus (NASDAQ:LNTH - Get Free Report) had its price target cut by stock analysts at B. Riley from $122.00 to $109.00 in a research note issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the medical equipment provider's stock. B. Riley's price objective points to a potential upside of 35.00% from the company's previous close.

A number of other research analysts also recently commented on the stock. Truist Financial lowered their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus currently has an average rating of "Buy" and an average price target of $130.50.

Lantheus Stock Up 0.2%

NASDAQ:LNTH traded up $0.19 during trading hours on Monday, hitting $80.74. 999,230 shares of the stock traded hands, compared to its average volume of 1,014,638. The firm has a 50 day moving average price of $85.11 and a 200 day moving average price of $90.75. The firm has a market cap of $5.59 billion, a price-to-earnings ratio of 22.94 and a beta of 0.11. Lantheus has a fifty-two week low of $73.11 and a fifty-two week high of $126.89. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm's quarterly revenue was up .8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.69 earnings per share. Equities research analysts anticipate that Lantheus will post 6.01 earnings per share for the current year.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director now directly owns 318,650 shares of the company's stock, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 1.50% of the company's stock.

Institutional Trading of Lantheus

Several large investors have recently made changes to their positions in LNTH. Summit Securities Group LLC acquired a new stake in Lantheus in the 4th quarter worth approximately $37,000. Signaturefd LLC raised its position in shares of Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 116 shares during the period. Quarry LP lifted its stake in shares of Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock worth $48,000 after buying an additional 470 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after buying an additional 280 shares during the period. Finally, Hughes Financial Services LLC acquired a new position in Lantheus in the 1st quarter valued at $81,000. Institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.